Thirty-day outcomes in patients with acute pulmonary embolism who discontinued anticoagulant therapy before 90 days

Am Heart J. 2018 Dec;206:1-10. doi: 10.1016/j.ahj.2018.08.014. Epub 2018 Sep 5.

Abstract

Background: The contemporary natural history of patients with acute pulmonary embolism (PE) not receiving (or early discontinuing) anticoagulant therapy has not been consistently evaluated.

Objective: To assess the rate of the composite outcome of PE-related death, sudden death, or recurrent thromboembolism (VTE) within 30 days in all PE patients in whom anticoagulation was not administered or discontinued prematurely (<90 days of anticoagulation).

Methods: We used the RIETE database to assess the incidence rates (per 100 person-days) of the composite outcome within the subsequent 30 days. The risk of these events was compared to PE patients who were anticoagulated for ≥90 days.

Results: Of 34,447 PE recruited from 2001 to 2017, 47 (0.14%) did not receive anticoagulants and 1348 (3.91%) discontinued it before 90 days. Fatal PE developed in 25 (53%) of those without any anticoagulation and in 45 (3.33%) with premature discontinuations. Sudden death or non-fatal recurrent VTE occurred in 6 (0.45%) and 24 (1.48%) patients, respectively. The incidence of the primary outcome declined logarithmically from 6.36 per 100 patient-days in untreated patients to 0.32-0.13 in those treated for 8-90 days. During the first week of follow-up, the incidence rate was 13.9 and 0.60-0.31 per 100 patient-days, respectively. The adjusted odds of the primary outcome was 27 fold higher in untreated than in treated patients, and progressively decreased to 2.5-7 fold higher in patients treated for at least 7 days.

Conclusion: The incidence of the composite outcome was highest during the first week, and inversely and logarithmically correlated with the duration of anticoagulant therapy.

Publication types

  • Multicenter Study
  • Research Support, N.I.H., Extramural

MeSH terms

  • Acute Disease
  • Aged, 80 and over
  • Anticoagulants / therapeutic use*
  • Europe / epidemiology
  • Female
  • Follow-Up Studies
  • Humans
  • Incidence
  • Male
  • Pulmonary Embolism / diagnosis
  • Pulmonary Embolism / drug therapy*
  • Registries*
  • Retrospective Studies
  • Risk Factors
  • Survival Rate / trends
  • Thrombosis / epidemiology*
  • Thrombosis / etiology
  • Time Factors
  • Tomography, X-Ray Computed
  • United States / epidemiology
  • Withholding Treatment*

Substances

  • Anticoagulants